Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ RANK Polyclonal Antibody

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA141389
Description
Suggested positive control: Raw cell lysate.
RANK is a member of the tumor necrosis factor receptor (TNFR) family. The full length mouse RANK cDNA encodes a type I transmembrane protein with an extracellular and a cytoplasmic domain. The extracellular domain contains two potential N-linked glycosylation sites. RANK shares significant amino acid homology with other members of the TNFR family in its extracellular four cysteine-rich repeats. Human and murine RANK share 81% amino acid identity in their extracellular domains.
Specifications
| RANK | |
| Polyclonal | |
| Unconjugated | |
| TNFRSF11A | |
| CD265; FEO; LOH18CR1; loss of heterozygosity, 18, chromosomal region 1; Ly109; mRANK; ODFR; OFE; OPTB7; Osteoclast differentiation factor receptor; OSTS; Paget disease of bone 2; PDB2; Rank; receptor activator of NF-kappaB; receptor activator of NF-KB; receptor activator of nuclear factor-kappa B; RGD1563614; TNF receptor superfamily member 11a; Tnfrsf11a; TRANCER; TRANCE-R; tumor necrosis factor receptor superfamily member 11A; tumor necrosis factor receptor superfamily member 11a, NFKB activator; tumor necrosis factor receptor superfamily, member 11a, NFKB activator | |
| Rabbit | |
| Protein G | |
| RUO | |
| 21934, 8792 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Liquid |
| Western Blot | |
| 1.0 mg/mL | |
| PBS with 0.05% sodium azide | |
| O35305, Q9Y6Q6 | |
| TNFRSF11A | |
| A synthetic peptide corresponding to amino acid residues 603-613 of human RANK. | |
| 100 μg | |
| Primary | |
| Human, Mouse | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction